论文部分内容阅读
治疗急性心肌梗塞(AMI)的溶血栓疗法已经成为一种有效的治疗方法。溶血栓治疗包括新发展的第二代和第三代制剂(如复合茴香酰化纤维蛋白溶酶原链激酶激活剂—APSAC或anistreplase、尿激酶和前尿激酶)已广泛用于治疗急性局部缺血综合征,包括老年(70岁以上)AMI、迟发性AMI、无Q波AMI和变异型心绞痛。由链激酶纤维蛋白溶酶合成的APSAC以及产生它的理论已由Smith等于1979年报道的。根据其化学结构,可知茴香酰基团阻断位于纤维蛋白溶酶原分子上的纤维蛋白
Thrombolytic therapy for acute myocardial infarction (AMI) has become an effective treatment. Thrombolytic therapy, including newly-developed second- and third-generation agents such as the compound anisoylated plasminogen streptokinase activator-PSAAC or anistreplase, urokinase and pro-urokinase, has been used extensively to treat acute loci Blood syndrome, including elderly (over 70 years) AMI, delayed AMI, Q wave AMI and variant angina. The theory of APSAC synthesized by streptokinase and its production has been reported by Smith et al. In 1979. According to its chemical structure, it is known that anisoyloxy group blocks fibrin located on the plasminogen molecule